Literature DB >> 24155681

Evaluation of Prescribing Medications for Terminal Cancer Patients near Death: Essential or Futile.

Hye Ran Lee1, Seong Yoon Yi, Do Yeun Kim.   

Abstract

PURPOSE: The purpose of this study is to evaluate the prescription of essential or futile medications for terminal cancer patients during their final admission.
MATERIALS AND METHODS: We conducted a retrospective review of the medical charts of terminally ill cancer patients admitted to the Hemato-oncology Department of two teaching hospitals from March 1, 2007 to December 31, 2009. Essential medications were based on the drugs listed by the International Association for Hospice and Palliative Care, while futile medications were defined when short-term benefit to patients with respect to survival, quality of life, or symptom control was not anticipated.
RESULTS: A total of 196 patients were included. Among essential medications, strong opioids were the most frequently prescribed drugs during the last admission (62.2% fentanyl, 44.3% morphine), followed by megestrol (46.0%), and metoclopramide (37.2%); 51% of gastric protectors were prescribed with potential futility. Anti-hypertensive and antiglycemic agents were administered to those who experienced arterial blood pressure below 90 mm Hg (47.3%) or presented with a single measurement of fasting glucose below 50 mg/dL (10.7%), respectively. Statins were prescribed to 6.1% (12/196) of patients, and 75% of those prescriptions were regarded as futile.
CONCLUSION: Our data suggest that effective prescription of essential medications and withdrawal from futile medications should be actively reconciled for improvement of a patient's end-of-life care.

Entities:  

Keywords:  Drug therapy; Medical futility; Neoplasms; Symptom

Year:  2013        PMID: 24155681      PMCID: PMC3804734          DOI: 10.4143/crt.2013.45.3.220

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  18 in total

1.  Discontinuing cardiovascular medications at the end of life: lipid-lowering agents.

Authors:  Annette M Vollrath; Christian Sinclair; James Hallenbeck
Journal:  J Palliat Med       Date:  2005-08       Impact factor: 2.947

2.  Medical futility. Who decides?

Authors:  N S Jecker; R A Pearlman
Journal:  Arch Intern Med       Date:  1992-06

3.  Cancer symptom clusters: old concept but new data.

Authors:  Jordanka Kirkova; Declan Walsh; Aynur Aktas; Mellar P Davis
Journal:  Am J Hosp Palliat Care       Date:  2010-03-29       Impact factor: 2.500

4.  Prognostic significance of symptoms of hospitalised advanced cancer patients.

Authors:  Saskia C Teunissen; Alexander de Graeff; Hanneke C de Haes; Emile E Voest
Journal:  Eur J Cancer       Date:  2006-09-07       Impact factor: 9.162

5.  The last 48 hours of life.

Authors:  I Lichter; E Hunt
Journal:  J Palliat Care       Date:  1990       Impact factor: 2.250

6.  The use of midazolam and haloperidol in cancer patients at the end of life.

Authors:  L K Radha Krishna; V J Poulose; C Goh
Journal:  Singapore Med J       Date:  2012-01       Impact factor: 1.858

7.  Prescribing in palliative care as death approaches.

Authors:  David C Currow; James P Stevenson; Amy P Abernethy; John Plummer; Tania M Shelby-James
Journal:  J Am Geriatr Soc       Date:  2007-04       Impact factor: 5.562

8.  Statin prescribing patterns in a cohort of cancer patients with poor prognosis.

Authors:  Elizabeth A Bayliss; Michael R Bronsert; Liza M Reifler; Jennifer L Ellis; John F Steiner; Deanna B McQuillen; Diane L Fairclough
Journal:  J Palliat Med       Date:  2013-01-10       Impact factor: 2.947

9.  The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes.

Authors:  Dorit Pud; Sarah Ben Ami; Bruce A Cooper; Bradley E Aouizerat; Dorit Cohen; Ruth Radiano; Pnina Naveh; Rivka Nikkhou-Abeles; Vered Hagbi; Orly Kachta; Aliza Yaffe; Christine Miaskowski
Journal:  J Pain Symptom Manage       Date:  2007-12-21       Impact factor: 3.612

10.  Prescribing practices of a palliative care service.

Authors:  E B Curtis; T D Walsh
Journal:  J Pain Symptom Manage       Date:  1993-07       Impact factor: 3.612

View more
  4 in total

1.  Prescription trends at the end of life in a palliative care unit: observational study.

Authors:  Tatiana Peralta; Maria Margarida Castel-Branco; Paulo Reis-Pina; Isabel Vitória Figueiredo; Marília Dourado
Journal:  BMC Palliat Care       Date:  2022-05-04       Impact factor: 3.113

Review 2.  Deprescription in Advanced Cancer Patients.

Authors:  Ferraz Gonçalves
Journal:  Pharmacy (Basel)       Date:  2018-08-21

3.  The Use of Antidiabetic, Antihypertensive, and Lipid-lowering Medications in the Elderly Dying with Advanced Cancer.

Authors:  Mohammad Zafir Al-Shahri; Mahmoud Yassein Sroor; Wael Ali Ghareeb; Enas Noshy Aboulela; Wael Edesa
Journal:  Indian J Palliat Care       Date:  2019 Jan-Mar

Review 4.  Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review.

Authors:  Paul R Duberstein; Michael Chen; Michael Hoerger; Ronald M Epstein; Laura M Perry; Sule Yilmaz; Fahad Saeed; Supriya G Mohile; Sally A Norton
Journal:  J Pain Symptom Manage       Date:  2019-10-19       Impact factor: 3.612

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.